Cyclone Technology for Bioreactor Gas Stream Separation

This inventive concept applies the core technology of cyclones to separate particles from gas streams in bioreactors, enhancing efficiency and reducing contamination risks.

The original patent described cyclone technology for surface cleaning apparatuses, which have limitations in terms of scalability, complexity, and contamination risks. The new inventive concept addresses the need for efficient and sterile particle separation in bioreactors, which is critical for maintaining a healthy cell culture environment.

The inventive concept involves adapting the cyclone technology to operate in a sterile environment, specifically designed for bioreactors. The cyclone chamber is modified to accommodate a gas stream inlet, and the vortex finder is optimized for particle separation in a gas stream. The first end wall provides a first end surface of the cyclone chamber, ensuring efficient particle collection. The cyclone is connected to a particle collection chamber, allowing for efficient separation and collection of particles from the gas stream.

The new inventive concept introduces the novel application of cyclone technology to bioreactors, providing a sterile and efficient means of separating particles from gas streams. The inventive step lies in adapting the cyclone design to operate in a sterile environment, addressing a previously unmet need in the bioreactor industry.

Alternative embodiments may include modifying the cyclone chamber shape, adjusting the vortex finder design, or integrating additional features such as sensors or automation systems to optimize particle separation. Variations could include applying the cyclone technology to other industries, such as food processing or pharmaceuticals, where sterile particle separation is critical.

The inventive concept has significant commercial potential in the bioreactor industry, where efficient and sterile particle separation is essential for maintaining a healthy cell culture environment. The target market includes bioreactor manufacturers, biotechnology companies, and research institutions, with potential applications in vaccine development, cell therapy, and regenerative medicine.